Brief: Aim Vaccine Says FY Revenue RMB1.26 Billion
29/03/2023 16:12
March 29 (Reuters) - AIM Vaccine 6660.HK :
* FY REVENUE RMB1.26 BILLION VERSUS RMB1.57 BILLION
* FY LOSS ATTRIBUTABLE RMB319.6 MILLION VERSUS LOSS RMB692.8
MILLION
* SALES VOLUME OF VACCINE PRODUCTS IS EXPECTED TO INCREASE
STEADILY IN 2023
* EXPECT THAT DEMAND FOR MULTIVALENT COVID-19 VACCINES FOR
LATEST
VARIANT STRAIN WILL INCREASE IN CHINA
* IN CHINA, WE EXPECT A CONTINUOUSLY STRONG MARKET DEMAND
FOR OUR
EXISTING VACCINE PRODUCTS
* COVID-19 OUTBREAK IS NOT EXPECTED TO HAVE A MATERIAL
ADVERSE
IMPACT ON GROUP IN FUTURE
Source text for Eikon: ID:nHKS9Zj5r3
Further company coverage: 6660.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM Vaccine
See all newsBrief: AIM Vaccine Co Submits Application For Human Diploid Cell Rabies Vaccine In China
Brief: AIM Vaccine Says Tibet Bohai To Subscribe 37.4 Million Shares At RMB1.07 Each
Brief: AIM Vaccine Approves Issuance Of Up To 40 Million Domestic Shares
Brief: Aim Vaccine Says Serum-Free Rabies Vaccine Passes Inspection
Brief: AIM Vaccine Updates On 20-Valent Pneumococcal Polysaccharide Conjugate Vaccine